Recent Updates
Recently added Catalysts
ATYR Positive Sentiment

EFZO-FIT™: The Largest Ever Interventional Trial in Pulmonary Sarcoidosis

Tuesday, September 30, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: aTyr Pharma is conducting the largest interventional trial for pulmonary sarcoidosis, utilizing efzofitimod. This trial aims to evaluate the efficacy of this innovative treatment in improving patient outcomes. The initiative highlights the company's commitment to addressing unmet medical needs in this area.
Price reaction · baseline $0.7952 (2025-09-29 close) · hit after-hours · 2 other ATYR headline(s) in the window, move may be shared
day 0 close
-9.3%
day 1 · peak
-13.2%
day 3
-2.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Largest interventional trial in pulmonary sarcoidosis.
  • Focus on innovative treatment with efzofitimod.
  • Potential to significantly impact patient outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
5.7%
average across 7 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kg
Phase 3 · Pulmonary Sarcoidosis

Full Press Release Details

• Company About Us Leadership Team Board of Directors Advisors Contact
• Our Science Extracellular t RNA Synthetase Biology Intellectual Property Publications, Posters and Presentations
• R&D Pipeline Efzofitimod Research Programs Pangu
• Patients Clinical Trials About Pulmonary Sarcoidosis About SSc-ILD EFZO-CONNECT ™ Expanded Access Policy
• Careers Working at aTyr Career Opportunities
• Investors and Media Corporate Governance Board of Directors Board Committees News Releases SEC Filings Stock Information Analyst Coverage Investor Alerts Events and Webcasts Media
• Privacy Policy
• About Us
• Leadership Team
• Board of Directors
• Advisors
• Contact
• Extracellular t RNA Synthetase Biology
• Intellectual Property
• Publications, Posters and Presentations
• Pipeline
• Efzofitimod
• Research Programs
• Pangu
• Clinical Trials
• About Pulmonary Sarcoidosis
• About SSc-ILD
• EFZO-CONNECT ™
• Expanded Access Policy
• Working at aTyr
• Career Opportunities
• Corporate Governance Board of Directors Board Committees
• News Releases
• SEC Filings
• Stock Information
• Analyst Coverage
• Investor Alerts
• Events and Webcasts
• Media
• Board of Directors
• Board Committees

Frequently Asked Questions

What is the EFZO-FIT™ trial?

The EFZO-FIT™ trial is the largest interventional study focused on pulmonary sarcoidosis.

What treatment is being tested in the trial?

The trial is testing efzofitimod as a potential treatment for pulmonary sarcoidosis.

Why is this trial significant?

It represents a major effort to address unmet medical needs in pulmonary sarcoidosis.

ShareAdd on Google
Tags: ATYR Viatris Investor Conferences Healthcare aTyr Pharma efzofitimod pulmonary sarcoidosis clinical trial interventional trial
Last updated: Sep 30, 2025

Biotech snapshot

Cash runway
$57M liquidity · $3M/mo burn
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kgPhase 3
Pulmonary Sarcoidosis →

Catalyst track record

+41%
best trade around ATYR's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ATYR.

See every catalyst's timing & PoA →